Genmab A/S (NASDAQ:GMAB) Issues Quarterly Earnings Results, Beats Expectations By $0.29 EPS

Genmab A/S (NASDAQ:GMAB - Get Free Report) released its quarterly earnings results on Wednesday. The company reported $0.57 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.29, Zacks reports. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. Genmab A/S updated its FY 2025 guidance to EPS.

Genmab A/S Trading Up 1.8 %

NASDAQ GMAB traded up $0.38 on Friday, hitting $21.30. 2,417,574 shares of the company's stock traded hands, compared to its average volume of 1,682,134. Genmab A/S has a 1-year low of $18.64 and a 1-year high of $31.88. The firm's 50-day moving average price is $20.65 and its two-hundred day moving average price is $23.11. The firm has a market capitalization of $14.10 billion, a PE ratio of 20.68, a P/E/G ratio of 0.54 and a beta of 0.96.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price for the company in a research note on Thursday. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Finally, Sanford C. Bernstein upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $42.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.